New drug QLS7305 tested in healthy volunteers – first step for future therapies
NCT ID NCT07313150
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 1 trial will test the safety and tolerability of QLS7305, an investigational drug, in 60 healthy Chinese adults. Participants will receive either single or multiple doses of the drug or a placebo, along with preventive antibiotics. The study focuses on how the body processes the drug and its effects on the immune system, with no direct treatment benefit for volunteers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QLS7305 injection
What could go wrong
This is a very early Phase 1 study in healthy volunteers, so it is not designed to test any treatment effect. The drug may prove unsafe or ineffective in future patient studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS - MALE AND FEMALE are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••